Ataluren Fails to Lower Seizure Frequency in Children in Small Trial

Ataluren Fails to Lower Seizure Frequency in Children in Small Trial

294465

Ataluren Fails to Lower Seizure Frequency in Children in Small Trial

Ataluren, in development by PTC Therapeutics as a possible treatment for Dravet syndrome, showed an acceptable safety profile in a small clinical trial. That trial, conducted at a single site in New York City, involved 15 children with either Dravet syndrome due to mutations in the CDKL5 gene, or a related seizure disorder. However, the investigational medication did not reduce the frequency of seizures among the Dravet patients nor significantly improve other measurements of function…

You must be logged in to read/download the full post.